Literature DB >> 15673298

IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.

Jan Novak1, Milan Tomana, Karel Matousovic, Rhubell Brown, Stacy Hall, Lea Novak, Bruce A Julian, Robert J Wyatt, Jiri Mestecky.   

Abstract

BACKGROUND: Sera of patients with IgA nephropathy (IgAN) contain circulating immune complexes (CIC) composed of galactose-deficient IgA1 complexed with antiglycan antibodies. The role of these CIC in the pathogenesis of IgAN is not known.
METHODS: We studied how proliferation of cultured mesangial cells (MC) is affected by CIC prepared from sera of IgAN patients and healthy control subjects using size-exclusion chromatography. CIC-containing fractions were added to serum-starved MC in culture, and cell proliferation was measured using (3)H-thymidine incorporation. The results were confirmed by staining MC using an antibody against proliferating cell nuclear antigen.
RESULTS: The incubation of starved MC with serum fractions with M(r) 800 to 900 kD, rich with galactose-deficient IgA1, stimulated proliferation, while fractions with smaller complexes were inhibitory. Furthermore, CIC-containing larger molecular mass fractions isolated from serum of an IgAN patient collected during an episode of macroscopic hematuria stimulated MC proliferation more than CIC obtained during a subsequent quiescent phase. To examine the role of IgA, we removed IgA1 from serum before fractionation. The resultant IgA1-depleted fractions were devoid of stimulatory IgA-CIC. Sera of IgAN patients were also fractionated after addition of desialylated galactose-deficient polymeric IgA1 to form additional immune complexes. Supplementation with a small quantity of this IgA1 increased cellular proliferation in assays using serum fractions of M(r)>/=800 to 900 kD; uncomplexed IgA1 did not affect MC proliferation significantly. In contrast, supplementation with a larger quantity of this IgA1 inhibited cellular proliferation in assays using serum fractions of M(r) 700 to 800 kD.
CONCLUSION: Overall, these findings suggest that CIC containing aberrantly glycosylated IgA1 affect proliferation of MC in vitro and, thus, likely play a role in the pathogenesis of IgAN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673298     DOI: 10.1111/j.1523-1755.2005.67107.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  93 in total

1.  Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.

Authors:  M Shimizu; N P Nikolov; K Ueno; K Ohta; R M Siegel; A Yachie; F Candotti
Journal:  Clin Immunol       Date:  2011-10-19       Impact factor: 3.969

Review 2.  Dysfunctions of the Iga system: a common link between intestinal and renal diseases.

Authors:  Christina Papista; Laureline Berthelot; Renato C Monteiro
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

Review 3.  IgA nephropathy and oxidative stress: news on clinically evaluated biomarkers hits the stage.

Authors:  Cheng Zhu; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-06-10       Impact factor: 2.370

4.  Development of Animal Models of Human IgA Nephropathy.

Authors:  Hitoshi Suzuki; Yusuke Suzuki; Jan Novak; Yasuhiko Tomino
Journal:  Drug Discov Today Dis Models       Date:  2014

5.  Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.

Authors:  Ali G Gharavi; Zina Moldoveanu; Robert J Wyatt; Catherine V Barker; Susan Y Woodford; Richard P Lifton; Jiri Mestecky; Jan Novak; Bruce A Julian
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

6.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

Review 7.  IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.

Authors:  Jing Xue; Li-Ping Zhu; Qiang Wei
Journal:  Glycoconj J       Date:  2013-06-20       Impact factor: 2.916

Review 8.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

9.  Update on immunoglobulin A nephropathy, Part I: Pathophysiology.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2015-09-06

10.  Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.

Authors:  Francois Berthoux; Hitoshi Suzuki; Lise Thibaudin; Hiroyuki Yanagawa; Nicolas Maillard; Christophe Mariat; Yasuhiko Tomino; Bruce A Julian; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.